成人超重和肥胖的流行病学概况和影响：Impact - o研究的多国结果。

IF 4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-08-19 DOI:10.1007/s12325-025-03333-1

Esther Artime, Erik Spaepen, Sarah Zimner-Rapuch, Anastasia Lampropoulou, Atif Adam, Xiaoyu Lin, Mengyuan Shang, Sarah Seager, Carel W. Le Roux, Dror Dicker

{"title":"成人超重和肥胖的流行病学概况和影响：Impact - o研究的多国结果。","authors":"Esther Artime, Erik Spaepen, Sarah Zimner-Rapuch, Anastasia Lampropoulou, Atif Adam, Xiaoyu Lin, Mengyuan Shang, Sarah Seager, Carel W. Le Roux, Dror Dicker","doi":"10.1007/s12325-025-03333-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>To estimate the recording rates and impact of overweight/obesity across selected countries in Europe and Asia–Pacific.</p><h3>Methods</h3><p>IMPACT-O was a retrospective cohort study of electronic medical records and claims databases from France, Germany, Italy, Spain, the UK, Australia, and Japan. Recording levels and the number of adults with overweight/obesity [based on diagnostic codes and/or body mass index (BMI)] during 2018–2022 were estimated. BMI thresholds/categories and obesity-related complications (ORCs) were described for adults with ≥ 1 BMI record of ≥ 25.0 kg/m<sup>2</sup> and ≥ 12 months observation before the index date.</p><h3>Results</h3><p>The number of active subjects across databases ranged from 1,203,674 to 22,413,902. BMI was recorded for 4.8–38.9% of active patients. The number of adults with overweight/obesity ranged from 3.5% in Australia to 24.9% in the UK. The percentage of individuals with BMI > 25 to < 30 kg/m<sup>2</sup> ranged from 43.6% in Spain to 77.9% in Japan; the percentage with BMI ≥ 30.0 kg/m<sup>2</sup> ranged from 22.1% in Japan to 54.8% in Spain. Among those with overweight/obesity, the percentage with diagnosis codes in their records ranged from 2.9% in France to 50.1% in Germany. Most (59.6–85.0%) individuals had ≥ 1 ORC; 35.9–65.8% had multimorbidity. The most frequently recorded ORCs were hypertension, dyslipidemia, depression, and type 2 diabetes.</p><h3>Conclusion</h3><p>Only a small proportion of people with overweight/obesity are formally diagnosed in healthcare databases. Most present with ≥ 1 ORC, commonly hypertension, dyslipidemia, depression, and type 2 diabetes.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 10","pages":"5148 - 5163"},"PeriodicalIF":4.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03333-1.pdf","citationCount":"0","resultStr":"{\"title\":\"Epidemiology Landscape and Impact of Overweight and Obesity in Adults: Multi-country Results from the IMPACT-O Study\",\"authors\":\"Esther Artime, Erik Spaepen, Sarah Zimner-Rapuch, Anastasia Lampropoulou, Atif Adam, Xiaoyu Lin, Mengyuan Shang, Sarah Seager, Carel W. Le Roux, Dror Dicker\",\"doi\":\"10.1007/s12325-025-03333-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>To estimate the recording rates and impact of overweight/obesity across selected countries in Europe and Asia–Pacific.</p><h3>Methods</h3><p>IMPACT-O was a retrospective cohort study of electronic medical records and claims databases from France, Germany, Italy, Spain, the UK, Australia, and Japan. Recording levels and the number of adults with overweight/obesity [based on diagnostic codes and/or body mass index (BMI)] during 2018–2022 were estimated. BMI thresholds/categories and obesity-related complications (ORCs) were described for adults with ≥ 1 BMI record of ≥ 25.0 kg/m<sup>2</sup> and ≥ 12 months observation before the index date.</p><h3>Results</h3><p>The number of active subjects across databases ranged from 1,203,674 to 22,413,902. BMI was recorded for 4.8–38.9% of active patients. The number of adults with overweight/obesity ranged from 3.5% in Australia to 24.9% in the UK. The percentage of individuals with BMI > 25 to < 30 kg/m<sup>2</sup> ranged from 43.6% in Spain to 77.9% in Japan; the percentage with BMI ≥ 30.0 kg/m<sup>2</sup> ranged from 22.1% in Japan to 54.8% in Spain. Among those with overweight/obesity, the percentage with diagnosis codes in their records ranged from 2.9% in France to 50.1% in Germany. Most (59.6–85.0%) individuals had ≥ 1 ORC; 35.9–65.8% had multimorbidity. The most frequently recorded ORCs were hypertension, dyslipidemia, depression, and type 2 diabetes.</p><h3>Conclusion</h3><p>Only a small proportion of people with overweight/obesity are formally diagnosed in healthcare databases. Most present with ≥ 1 ORC, commonly hypertension, dyslipidemia, depression, and type 2 diabetes.</p></div>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\"42 10\",\"pages\":\"5148 - 5163\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s12325-025-03333-1.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12325-025-03333-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03333-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

前言：评估欧洲和亚太地区某些国家超重/肥胖的记录率和影响。方法：IMPACT-O是一项来自法国、德国、意大利、西班牙、英国、澳大利亚和日本的电子医疗记录和索赔数据库的回顾性队列研究。估算了2018-2022年期间（根据诊断代码和/或体重指数）超重/肥胖成人的记录水平和人数。BMI阈值/分类和肥胖相关并发症（ORCs）描述为BMI≥1记录≥25.0 kg/m2和指数日期前观察≥12个月的成年人。结果：数据库中活跃受试者的数量从1,203,674到22,413,902不等。4.8-38.9%的运动患者记录BMI。成年人超重/肥胖的比例从澳大利亚的3.5%到英国的24.9%不等。BMI介于25至2之间的个体比例从西班牙的43.6%到日本的77.9%不等；BMI≥30.0 kg/m2的比例从日本的22.1%到西班牙的54.8%不等。在超重/肥胖人群中，记录中有诊断代码的比例从法国的2.9%到德国的50.1%不等。大多数个体（59.6 ~ 85.0%）ORC≥1；35.9 ~ 65.8%为多病。最常见的orc是高血压、血脂异常、抑郁症和2型糖尿病。结论：只有一小部分超重/肥胖患者在医疗数据库中被正式诊断。多数表现为ORC≥1，常见的有高血压、血脂异常、抑郁症和2型糖尿病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Epidemiology Landscape and Impact of Overweight and Obesity in Adults: Multi-country Results from the IMPACT-O Study

Introduction

To estimate the recording rates and impact of overweight/obesity across selected countries in Europe and Asia–Pacific.

Methods

IMPACT-O was a retrospective cohort study of electronic medical records and claims databases from France, Germany, Italy, Spain, the UK, Australia, and Japan. Recording levels and the number of adults with overweight/obesity [based on diagnostic codes and/or body mass index (BMI)] during 2018–2022 were estimated. BMI thresholds/categories and obesity-related complications (ORCs) were described for adults with ≥ 1 BMI record of ≥ 25.0 kg/m² and ≥ 12 months observation before the index date.

Results

The number of active subjects across databases ranged from 1,203,674 to 22,413,902. BMI was recorded for 4.8–38.9% of active patients. The number of adults with overweight/obesity ranged from 3.5% in Australia to 24.9% in the UK. The percentage of individuals with BMI > 25 to < 30 kg/m² ranged from 43.6% in Spain to 77.9% in Japan; the percentage with BMI ≥ 30.0 kg/m² ranged from 22.1% in Japan to 54.8% in Spain. Among those with overweight/obesity, the percentage with diagnosis codes in their records ranged from 2.9% in France to 50.1% in Germany. Most (59.6–85.0%) individuals had ≥ 1 ORC; 35.9–65.8% had multimorbidity. The most frequently recorded ORCs were hypertension, dyslipidemia, depression, and type 2 diabetes.

Conclusion

Only a small proportion of people with overweight/obesity are formally diagnosed in healthcare databases. Most present with ≥ 1 ORC, commonly hypertension, dyslipidemia, depression, and type 2 diabetes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.